Researchers identified a distinct CD81+ senescent-like fibroblast population in periodontitis that accumulates in gum tissue and drives chronic inflammation. These cells secrete SASP factors like IL-6 and activate neutrophils via complement protein C3 signaling through C3aR1. Using human gingival samples, mouse ligature-induced periodontitis models, and single-cell RNA sequencing, the team showed senescent cells peak at day 7 post-ligation. Targeting these cells with the senolytic drug Navitoclax or metformin reduced inflammation and alveolar bone loss, suggesting cellular senescence is a viable therapeutic target in periodontitis.
